Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Chuong, MD; Kaiser, A; Khan, F; Parikh, P; Ben-Josef, E; Crane, C; Brunner, T; Okumura, T; Schreuder, N; Bentzen, SM; Gutierrez, A; Mendez, Romero, A; Yoon, SM; Sharma, N; Kim, TH; Kishi, K; Moeslein, F; Hoffe, S; Schefter, T; Hanish, S; Scorsetti, M; Apisarnthanarax, S.
Consensus Report From the Miami Liver Proton Therapy Conference.
Front Oncol. 2019; 9:457
Doi: 10.3389/fonc.2019.00457
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- An international group of 22 liver cancer experts from 18 institutions met in Miami, Florida to discuss the optimal utilization of proton beam therapy (PBT) for primary and metastatic liver cancer. There was consensus that PBT may be preferred for liver cancer patients expected to have a suboptimal therapeutic ratio from XRT, but that PBT should not be preferred for all patients. Various clinical scenarios demonstrating appropriateness of PBT vs. XRT were reviewed.
- Find related publications in this database (Keywords)
-
proton therapy
-
liver cancer
-
hepatocellular carcinoma (HCC)
-
cholangiocarcinoma (CC)
-
liver metastases